Augmedix, Inc.

2023 Q3 Form 10-Q Financial Statement

#000121390023066821 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q4

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $21.59M $24.55M $21.99M
YoY Change -20.03% -18.13% -46.7%
Cash & Equivalents $21.59M $24.55M $21.25M
Short-Term Investments
Other Short-Term Assets $2.040M $2.086M $5.299M
YoY Change -59.99% 20.65% 165.88%
Inventory
Prepaid Expenses
Receivables $9.446M $9.433M $6.354M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $33.07M $36.07M $33.64M
YoY Change -10.98% -0.94% -33.29%
LONG-TERM ASSETS
Property, Plant & Equipment $3.000M $2.608M $1.573M
YoY Change 130.24% 124.25% 60.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.470M $1.541M $951.0K
YoY Change 28.05% 42.82% 245.82%
Total Long-Term Assets $7.763M $7.778M $0.00
YoY Change 87.47% -100.0%
TOTAL ASSETS
Total Short-Term Assets $33.07M $36.07M $33.64M
Total Long-Term Assets $7.763M $7.778M $0.00
Total Assets $40.83M $43.85M $33.64M
YoY Change 9.92% 8.1% -34.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.816M $1.604M $1.563M
YoY Change 28.16% 1.26% 14.51%
Accrued Expenses $5.472M $4.812M $5.321M
YoY Change 15.2% 31.05% 24.94%
Deferred Revenue $7.254M
YoY Change 16.29%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $7.500M $5.000M $15.13M
YoY Change -50.11% 908.93%
Total Short-Term Liabilities $24.70M $21.26M $32.17M
YoY Change -19.54% 68.59% 129.92%
LONG-TERM LIABILITIES
Long-Term Debt $12.61M $14.93M $11.38M
YoY Change -4.16% 0.0% -14.64%
Other Long-Term Liabilities $2.790M $3.666M $1.477M
YoY Change 69.19% 97.84% 121.11%
Total Long-Term Liabilities $15.40M $18.60M $12.86M
YoY Change 4.0% 10.8% -8.17%
TOTAL LIABILITIES
Total Short-Term Liabilities $24.70M $21.26M $32.17M
Total Long-Term Liabilities $15.40M $18.60M $12.86M
Total Liabilities $40.10M $39.86M $32.17M
YoY Change 30.62% 35.59% 14.91%
SHAREHOLDERS EQUITY
Retained Earnings -$140.5M -$136.1M -$125.8M
YoY Change 16.9% 18.2% 23.65%
Common Stock $142.1M $4.000K $4.000K
YoY Change 3551925.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $734.0K $3.989M $1.466M
YoY Change
Total Liabilities & Shareholders Equity $40.83M $43.85M $33.64M
YoY Change 9.92% 8.1% -34.91%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q4

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40890
dei Entity Registrant Name
EntityRegistrantName
AUGMEDIX, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-3299164
dei Entity Address Address Line1
EntityAddressAddressLine1
111 Sutter Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1300
dei Entity Address City Or Town
EntityAddressCityOrTown
San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94104
dei City Area Code
CityAreaCode
(888)
dei Local Phone Number
LocalPhoneNumber
669-4885
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
AUGX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
40790857 shares
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24551000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21251000 usd
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
125000 usd
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
125000 usd
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
128000 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
102000 usd
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9433000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6354000 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1961000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1820000 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
36070000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
29550000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2608000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1573000 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3629000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1567000 usd
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
584000 usd
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
612000 usd
CY2023Q2 us-gaap Deposits Assets
DepositsAssets
957000 usd
CY2022Q4 us-gaap Deposits Assets
DepositsAssets
339000 usd
CY2023Q2 us-gaap Assets
Assets
43848000 usd
CY2022Q4 us-gaap Assets
Assets
33641000 usd
CY2023Q2 us-gaap Loans Payable Current
LoansPayableCurrent
5000000 usd
CY2022Q4 us-gaap Loans Payable Current
LoansPayableCurrent
3750000 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1604000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1563000 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4812000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5321000 usd
CY2023Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
7858000 usd
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
7254000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1471000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
872000 usd
CY2023Q2 us-gaap Customer Deposits Current
CustomerDepositsCurrent
516000 usd
CY2022Q4 us-gaap Customer Deposits Current
CustomerDepositsCurrent
554000 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
21261000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19314000 usd
CY2023Q2 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
14932000 usd
CY2022Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
11384000 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2437000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
968000 usd
CY2023Q2 us-gaap Other Liabilities
OtherLiabilities
1229000 usd
CY2022Q4 us-gaap Other Liabilities
OtherLiabilities
509000 usd
CY2023Q2 us-gaap Liabilities
Liabilities
39859000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
32175000 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.1000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.1000
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40800078 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40800078 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37442663 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37442663 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
4000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
4000 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
140819000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
127693000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-136063000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-125791000 usd
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-771000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-440000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
3989000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1466000 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
43848000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
33641000 usd
CY2023Q2 us-gaap Revenues
Revenues
10780000 usd
CY2022Q2 us-gaap Revenues
Revenues
7333000 usd
us-gaap Revenues
Revenues
20408000 usd
us-gaap Revenues
Revenues
14318000 usd
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
5715000 usd
CY2022Q2 us-gaap Cost Of Revenue
CostOfRevenue
4131000 usd
us-gaap Cost Of Revenue
CostOfRevenue
10957000 usd
us-gaap Cost Of Revenue
CostOfRevenue
8003000 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
5065000 usd
CY2022Q2 us-gaap Gross Profit
GrossProfit
3202000 usd
us-gaap Gross Profit
GrossProfit
9451000 usd
us-gaap Gross Profit
GrossProfit
6315000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4760000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4172000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8967000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8219000 usd
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2649000 usd
CY2022Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2320000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5212000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4640000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2590000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2649000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5300000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4929000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
9999000 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
9141000 usd
us-gaap Operating Expenses
OperatingExpenses
19479000 usd
us-gaap Operating Expenses
OperatingExpenses
17788000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4934000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5939000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-10028000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-11473000 usd
CY2023Q2 us-gaap Interest Expense Other
InterestExpenseOther
558000 usd
CY2022Q2 us-gaap Interest Expense Other
InterestExpenseOther
385000 usd
us-gaap Interest Expense Other
InterestExpenseOther
966000 usd
us-gaap Interest Expense Other
InterestExpenseOther
986000 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
276000 usd
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
4000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
438000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
9000 usd
CY2022Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1097000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1097000 usd
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
69000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
69000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
303000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
84000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
437000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
208000 usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-48000 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1394000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-160000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1866000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4982000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7333000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10188000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13339000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
51000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
84000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
21000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-5033000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-7335000 usd
us-gaap Net Income Loss
NetIncomeLoss
-10272000 usd
us-gaap Net Income Loss
NetIncomeLoss
-13360000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-298000 usd
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-131000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-331000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-140000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-5331000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-7466000 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-10603000 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-13500000 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.2
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43607984 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37416095 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40566425 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37406090 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1466000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
85000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
533000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-33000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5239000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-3188000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11845000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
93000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
570000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-298000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-5033000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
3989000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
23684000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
424000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-9000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-6025000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
18087000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
72000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
491000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-131000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-7335000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
11190000 usd
us-gaap Net Income Loss
NetIncomeLoss
-10272000 usd
us-gaap Net Income Loss
NetIncomeLoss
-13360000 usd
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
541000 usd
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
389000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1098000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
915000 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
255000 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
264000 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
200000 usd
augx Noncash Portion Of Loss On Debt Extinguishment
NoncashPortionOfLossOnDebtExtinguishment
1087000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
69000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
437000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
332000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
26000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
12000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3105000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2468000 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
250000 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-46000 usd
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
442000 usd
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
289000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-102000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
238000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-567000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-410000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
604000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-375000 usd
us-gaap Increase Decrease In Customer Deposits
IncreaseDecreaseInCustomerDeposits
-38000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-429000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-373000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12175000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8856000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1475000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
615000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1475000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-615000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
5000000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
15000000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
16125000 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
55000 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
142000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11845000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
179000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
19000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16969000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1248000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
-47000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
-90000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3272000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10809000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21988000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41587000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25260000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30778000 usd
us-gaap Interest Paid Net
InterestPaidNet
667000 usd
us-gaap Interest Paid Net
InterestPaidNet
815000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
8000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
13000 usd
augx Property Plant And Equipments In Accounts Payable
PropertyPlantAndEquipmentsInAccountsPayable
155000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2498000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2599000 usd
augx Fair Value Of Warrants Issued In Connection With Loan
FairValueOfWarrantsIssuedInConnectionWithLoan
492000 usd
augx Fair Value Of Warrants Issued In Connection With Loan
FairValueOfWarrantsIssuedInConnectionWithLoan
72000 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>1. Organization and Nature of Business</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Augmedix, Inc. (the “Company”, “we” or “our”) was incorporated in 2013 and launched its commercial real-time, remote documentation services in 2014.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Augmedix delivers industry-leading, ambient medical documentation and data products to healthcare systems, physician practices, hospitals, and telemedicine practitioners.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Augmedix is on a mission to help clinicians and patients form a human connection at the point of care without the intrusion of technology. Augmedix’s products digitize natural physician-patient conversations and convert it to medical notes in real time, which are seamlessly transferred to the Electronic Health Record (“EHR”) system. To achieve this, the Company’s Notebuilder Platform uses Automated Speech Recognition, Natural Language Processing, including Large Language Models, and proprietary structured data sets, supported by medical documentation specialists.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Leveraging this platform, Augmedix’s products relieve clinicians of administrative burden, in turn, reducing burnout and increasing both clinician and patient satisfaction.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Augmedix is headquartered in San Francisco, CA, with offices in three (3) countries around the world.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">The Company has historically funded its operations primarily by debt and equity financings prior to the merger with Malo Holdings and subsequently funded its operations through cash proceeds obtained as part of the listing on the OTC market and the listing on Nasdaq. As of June 30, 2023, the Company’s existing sources of liquidity included cash, cash equivalents and restricted cash of $25.3 million, plus up to $5.0 million in incremental capital available through the SVB Loan Agreement and an additional $5.0 million through the Equity Line of Credit with Redmile Group, LLC, which may be utilized starting in the second half of 2024. The Company has a limited history of operations and has incurred negative cash flows from operating activities and losses from operations in the past as reflected in the accumulated deficit of $136.1 million as of June 30, 2023. <span>The Company has relied on debt and equity financing to fund operations to date and expects losses and negative cash flows to continue, primarily as a result of continued research, development, and marketing efforts. The Company’s cash balance will provide sufficient resources to meet working capital needs for over twelve months from the filing date of the </span>June 30<span>, 2023 Form 10-Q. Over the longer term, if the Company does not generate sufficient revenue from new and existing products, additional debt or equity financing may be required along with a reduction in expenditures. Additionally, there is no assurance if the Company requires additional future financing that such financing will be available on terms which are acceptable to it, or at all.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks and Uncertainties</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company is subject to a number of risks associated with companies at a similar stage, including dependence on key personnel, competition from similar products and larger companies, ongoing changes within the industry, ability to obtain adequate financing to support growth, the ability to attract and retain additional qualified personnel to manage the anticipated growth of the Company, and general economic conditions, including ongoing economic impacts from the conflict in Ukraine, economic volatility caused by increased interest rates, and instability within the banking system.</p>
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
25300000 usd
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
5000000 usd
CY2023Q2 us-gaap Line Of Credit
LineOfCredit
5000000 usd
CY2023Q2 us-gaap Fair Value Concentration Of Risk Cash And Cash Equivalents
FairValueConcentrationOfRiskCashAndCashEquivalents
23300000 usd
CY2023Q2 us-gaap Loans Payable Fair Value Disclosure
LoansPayableFairValueDisclosure
21300000 usd
CY2023Q2 us-gaap Short Term Non Bank Loans And Notes Payable
ShortTermNonBankLoansAndNotesPayable
19900000 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001769804
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The preparation of the unaudited interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements and reported amounts of revenue and expenses during the reporting period. The Company’s significant estimates and judgments involve the average period of benefit associated with costs capitalized to obtain a revenue contract, incremental borrowing rate, internal-use software development costs, fair value of warrants issued, and stock-based compensation, including the underlying fair value of the Company’s common stock for grants issued when the Company was a private company. Actual results could differ from those estimates.</p>
CY2023Q2 us-gaap Business Combination Separately Recognized Transactions Net Gains And Losses
BusinessCombinationSeparatelyRecognizedTransactionsNetGainsAndLosses
300000 usd
CY2022Q2 us-gaap Business Combination Separately Recognized Transactions Net Gains And Losses
BusinessCombinationSeparatelyRecognizedTransactionsNetGainsAndLosses
100000 usd
us-gaap Business Combination Separately Recognized Transactions Net Gains And Losses
BusinessCombinationSeparatelyRecognizedTransactionsNetGainsAndLosses
300000 usd
us-gaap Business Combination Separately Recognized Transactions Net Gains And Losses
BusinessCombinationSeparatelyRecognizedTransactionsNetGainsAndLosses
100000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Concentrations of Credit Risk and Major Customers</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Financial instruments at June 30, 2023 and 2022 that potentially subject the Company to concentration of credit risk consist primarily of cash and accounts receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company’s cash is deposited with major financial institutions in the U.S., Bangladesh and India. At times, deposits in financial institutions located in the U.S. may be in excess of the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation (“FDIC”). Cash deposits at foreign financial institutions are not insured by government agencies of Bangladesh and India. To date, the Company has not experienced any losses on its cash deposits. The Company keeps a majority of its cash in quoted and highly-liquid money market funds.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company’s accounts receivable are derived from revenue from customers located in the U.S. Major customers are defined as those generating revenue in excess of 10% of the Company’s annual revenue. The Company had three major customers during the three and six months ended June 30, 2023. Revenues from these major customers accounted for 20%, 14% and 12% of revenue for the three months ended June 30, 2023 and 19%, 14% and 12% of revenue for the six months ended June 30, 2023. The Company had three major customers during the three and six months ended June 30, 2022. Revenues from these major customers accounted for 18%, 17% and 12% of revenue for the three months ended June 30, 2022 and 19%, 17% and 12% of revenue for the six months ended June 30, 2022. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Four customers account for 10% or more of the accounts receivable, with balances of $2.5 million, $1.2 million, $1.2 million and $1.2 million at June 30, 2023. Two customers account for 10% or more of the accounts receivable, with balances of $1.4 million and $0.7 million at December 31, 2022. </p>
augx Accounts Receivable Percentage
AccountsReceivablePercentage
0.10 pure
CY2022 augx Accounts Receivable Percentage
AccountsReceivablePercentage
0.10 pure
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
279000 usd
CY2023Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
4812000 usd
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
5321000 usd
CY2021Q1 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
17000000 usd
CY2021Q1 us-gaap Customer Funds
CustomerFunds
15000000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24551000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29988000 usd
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
125000 usd
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
125000 usd
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
584000 usd
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
665000 usd
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
25260000 usd
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
30778000 usd
us-gaap Revenue Recognition Allowances
RevenueRecognitionAllowances
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Revenue Recognition</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">ASC Topic 606, <i>Revenue from Contracts with Customers</i>, outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers. The core principle, involving a five-step process, of the revenue model is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company derives its revenue through a stand-ready recurring subscription model. The Company enters into contracts or agreements with its customers with a general initial term of one year. Customers are invoiced in advance and generally pay an upfront implementation fee. The upfront implementation fee is deferred and recognized over the period the customer benefits and customer prepayments are deferred and included in the accompanying unaudited interim condensed consolidated balance sheets in deferred revenues. Revenues are recognized over time as the professional services are provided to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. The customer receives the benefit of our stand-ready scribing services as we perform them.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As permitted under the practical expedient available under ASU 2014-09, the Company does not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less, (ii) contracts with variable consideration that is allocated entirely to unsatisfied performance obligations or to a wholly unsatisfied promise accounted for under the series guidance, and (iii) contracts for which the Company recognizes revenue for the amount at which the Company has the right to invoice for services performed. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company’s revenues are earned from customers located only in the U.S. After the initial term, contracts are cancellable by the customer at their discretion typically with a 90 day notice.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company determines revenue recognition through the following steps:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"> </td> <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification of the contract, or contracts, with a customer;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification of the performance obligations in the contract;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determination of the transaction price;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocation of the transaction price to the performance obligations in the contract; and</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognition of revenue when, or as, the Company satisfies a performance obligation.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Except for two U.S. state sales tax jurisdictions, applicable taxes, including local, sales, value added tax, etc., are the responsibility of the customer to self-assess and remit to proper tax authorities. Revenue is recognized net of any sales taxes.</p>
CY2023Q2 us-gaap Research And Development Expense Software Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost
200000 usd
CY2021Q4 us-gaap Customer Funds
CustomerFunds
2000000 usd
CY2021Q4 us-gaap Customer Funds
CustomerFunds
6000000 usd
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
4800000 usd
CY2021Q4 us-gaap Investment Interest Rate Floor
InvestmentInterestRateFloor
0.12 pure
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
7254 usd
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
6238 usd
augx Deferral Of Revenue
DeferralOfRevenue
21064 usd
CY2022 augx Deferral Of Revenue
DeferralOfRevenue
31949 usd
us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
20460 usd
CY2022 us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
30933 usd
CY2023Q2 us-gaap Deferred Revenue
DeferredRevenue
7858 usd
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
7254 usd
CY2023Q2 us-gaap Advertising Expense
AdvertisingExpense
200000 usd
CY2022Q2 us-gaap Advertising Expense
AdvertisingExpense
200000 usd
us-gaap Advertising Expense
AdvertisingExpense
400000 usd
us-gaap Advertising Expense
AdvertisingExpense
500000 usd
us-gaap Supplemental Deferred Purchase Price
SupplementalDeferredPurchasePrice
3000000 usd
us-gaap Principal Transactions Revenue
PrincipalTransactionsRevenue
1100000 usd
CY2023Q2 us-gaap Securities Loaned Or Sold Under Agreements To Repurchase Fair Value Disclosure
SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseFairValueDisclosure
200000 usd
CY2023Q2 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0 pure
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
14569242 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
10928658 shares
us-gaap Marketing Expense
MarketingExpense
100000 usd
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9440000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7925000 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6832000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6352000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2608000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1573000 usd
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000 usd
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
500000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
400000 usd
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2191000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3587000 usd
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
569000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
466000 usd
CY2023Q2 augx Accrued Vendor Partner Liabilities
AccruedVendorPartnerLiabilities
1069000 usd
CY2022Q4 augx Accrued Vendor Partner Liabilities
AccruedVendorPartnerLiabilities
871000 usd
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
680000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
118000 usd
CY2023Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
303000 usd
augx Svb Loan Agreement Description
SVBLoanAgreementDescription
in connection with a prepayment by the Company of all borrowings under the term loan facility, with the following prepayment fee payable: (a) 2.50% of the outstanding principal amount of the borrowings under the term loan facility at the time of such prepayment if it occurs prior to the first anniversary of the Effective Date, (b) 1.50% of the outstanding principal amount of the borrowings under the term loan facility at the time of such prepayment if it occurs on or after the first anniversary of the effective date but prior to the second anniversary of the Effective Date, and (c) 0.50% of the outstanding principal amount of the borrowings under the term loan facility at the time of such prepayment if it occurs on or after the second anniversary of the Effective Date but prior to the term loan facility’s maturity date.
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
10000000 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
10000000 usd
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
20000000 usd
CY2023Q2 us-gaap Other Long Term Debt
OtherLongTermDebt
1000000 usd
CY2023Q2 us-gaap Subordinated Debt
SubordinatedDebt
21000000 usd
CY2023Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1068000 usd
CY2023Q2 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
19932000 usd
CY2023Q2 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
5000000 usd
CY2023Q2 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
14932000 usd
us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
10000000 usd
CY2023Q2 augx Adjusted Exercise Price Of Warrant Per Share
AdjustedExercisePriceOfWarrantPerShare
3.01
CY2023Q2 us-gaap Common Stock Other Shares Outstanding
CommonStockOtherSharesOutstanding
3125000 shares
CY2023Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.6
CY2023Q2 augx Exercise Price Per Share
ExercisePricePerShare
1.75
CY2023Q2 us-gaap Derivative Remaining Maturity1
DerivativeRemainingMaturity1
P7Y
CY2023Q2 us-gaap Common Stock Other Value Outstanding
CommonStockOtherValueOutstanding
5000000 usd
CY2023Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.6
CY2023Q2 us-gaap Common Stock Other Shares Outstanding
CommonStockOtherSharesOutstanding
9375342 shares
CY2022Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
9118739 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
616743 shares
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.068 pure
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.04 pure
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
5000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
5000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.571 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.544 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.039 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.019 pure
augx Share Based Compensation Arrangement By Shares Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.13
augx Share Based Compensation Arrangement By Shares Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.26
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
300000 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
27900000 usd
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
18200000 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
3800000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P2Y4M24D
CY2022Q4 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
4000 usd
CY2021Q1 augx Stock Based Compensation For Stock Options Description
StockBasedCompensationForStockOptionsDescription
the Company granted 727,922 stock options to the Company’s Chief Executive Officer (“CEO”) under the 2020 Plan with an exercise price of $3.00 per share. The options vest based on the CEO’s continued service in addition to the following terms: ●317,688 options vest in full when the closing price of the Company’s common stock reaches or exceeds $9.00 per share for a minimum of 20 out of 30 trading days after the Company became listed on Nasdaq. These options expire on March 3, 2031. ●46,273 options vest in full when the closing price of the Company’s common stock reaches or exceeds $9.00 per share for 20 out of 30 trading days after the Company became listed on the New York Stock Exchange or Nasdaq. Since the listing on Nasdaq, these options expire on March 22, 2031, instead of 2026. ●363,961 options vest in full when the closing price of the Company’s common stock reaches or exceeds $13.50 per share for 20 out of 30 trading days after the Company became listed on the New York Stock Exchange or Nasdaq. Since the listing on Nasdaq, these options expire on March 22, 2031, instead of 2026.
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Term Simplified Method
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermSimplifiedMethod
March 3, 2031
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.50 pure
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
3
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0077 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
400000 usd
us-gaap Employee Stock Ownership Plan Esop Compensation Expense
EmployeeStockOwnershipPlanESOPCompensationExpense
100000 usd
us-gaap Net Amount At Risk By Product And Guarantee Weighted Average Period Remaining1
NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1
P1Y
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
336000 usd
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
191000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
546000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
382000 usd
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
91000 usd
CY2022Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
90000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
175000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
175000 usd
CY2023Q2 us-gaap Lease Cost
LeaseCost
427000 usd
CY2022Q2 us-gaap Lease Cost
LeaseCost
281000 usd
us-gaap Lease Cost
LeaseCost
721000 usd
us-gaap Lease Cost
LeaseCost
557000 usd
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y9M18D
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y8M12D
us-gaap Operating Lease Payments
OperatingLeasePayments
485000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
422000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
728000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1478000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
768000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
630000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
674000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
198000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4476000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
568000 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
3908000 usd
CY2023Q2 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
1471000 usd
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2437000 usd
CY2021Q2 us-gaap Indefinite Lived Contractual Rights
IndefiniteLivedContractualRights
1800000 usd
augx Expenses Against Contract
ExpensesAgainstContract
400000 usd
CY2015Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P10Y
CY2023Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
100000 usd
CY2022Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
100000 usd
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
100000 usd
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
200000 usd
CY2023Q2 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
8000 usd
CY2023Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
38000 usd
CY2022Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
36000 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000 usd
us-gaap Other Expenses
OtherExpenses
700000 usd
CY2022 us-gaap Other Expenses
OtherExpenses
500000 usd
CY2023Q2 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
20000 usd
CY2022Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37406090 shares
CY2023Q2 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
us-gaap Other Noncash Expense
OtherNoncashExpense
usd
augx Noncash Portion Of Loss On Debt Extinguishment
NoncashPortionOfLossOnDebtExtinguishment
usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
us-gaap Increase Decrease In Customer Deposits
IncreaseDecreaseInCustomerDeposits
usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
augx Property Plant And Equipments In Accounts Payable
PropertyPlantAndEquipmentsInAccountsPayable
usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
usd
us-gaap Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate
pure
us-gaap Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate
pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31

Files In Submission

Name View Source Status
0001213900-23-066821-index-headers.html Edgar Link pending
0001213900-23-066821-index.html Edgar Link pending
0001213900-23-066821.txt Edgar Link pending
0001213900-23-066821-xbrl.zip Edgar Link pending
augx-20230630.xsd Edgar Link pending
f10q0623ex10-10_augmedixinc.htm Edgar Link pending
f10q0623ex10-1_augmedixinc.htm Edgar Link pending
f10q0623ex31-1_augmedixinc.htm Edgar Link pending
f10q0623ex31-2_augmedixinc.htm Edgar Link pending
f10q0623ex32-1_augmedixinc.htm Edgar Link pending
f10q0623ex32-2_augmedixinc.htm Edgar Link pending
f10q0623_augmedixinc.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
augx-20230630_cal.xml Edgar Link unprocessable
augx-20230630_lab.xml Edgar Link unprocessable
augx-20230630_pre.xml Edgar Link unprocessable
augx-20230630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
f10q0623_augmedixinc_htm.xml Edgar Link completed
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending